FirstBio

FirstBio Therapeutics is a clinical-stage biotechnology company headquartered in Seoul, South Korea, specializing in the discovery and development of first-in-class small molecule drugs. The company primarily focuses on neurodegenerative diseases, oncology, and rare diseases, leveraging its expertise in medicinal chemistry to target key pathological pathways. Its lead candidate, FB-101, is a potent and brain-penetrant c-Abl inhibitor currently undergoing Phase 1 clinical trials for the treatment of Parkinson's disease. Beyond its lead program, FirstBio is advancing a diverse pipeline that includes LRRK2 inhibitors for neurodegeneration and USP14 inhibitors for various cancers. The company aims to address high unmet medical needs by developing therapies that can modify disease progression rather than just managing symptoms. FirstBio maintains a global presence with operations in both South Korea and the United States to support its clinical development and business expansion efforts.